DIVISLAB:NSE:NSE-Divi's Laboratories Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 5375.8

Change

+2.95 (+0.05)%

Market Cap

USD 1,427.11B

Volume

0.52M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Divi's Laboratories Limited engages in the manufacture and sale of generic active pharmaceutical ingredients (APIs), intermediates, and nutraceuticals in India, North America, Asia, Europe, and internationally. The company also undertakes custom synthesis contract manufacturing services of APIs and intermediates; and supplies a range of carotenoids, such as beta carotene, astaxanthin, lycopene, and canthaxanthin, as well as other finished forms, including lutein, and vitamins to food, dietary supplement, and feed manufacturers industries. It also exports its products. The company was formerly known as Divi's Research Center and changed its name to Divi's Laboratories Limited in 1994. Divi's Laboratories Limited was incorporated in 1990 and is based in Hyderabad, India. Address: Divi Towers, Hyderabad, India, 500032

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-24 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
SUNPHARMA:NSE Sun Pharmaceutical Industries ..

+5.40 (+0.29%)

USD 4,405.17B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+13.25 (+0.38%)

USD 1,137.04B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-4.10 (-0.06%)

USD 1,107.90B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-3.70 (-0.35%)

USD 1,061.98B
MANKIND:NSE Mankind Pharma Ltd

+84.05 (+3.17%)

USD 1,020.50B
LUPIN:NSE Lupin Limited

+33.50 (+1.54%)

USD 1,014.97B
AUROPHARMA:NSE Aurobindo Pharma Limited

+20.20 (+1.36%)

USD 871.87B
ALKEM:NSE Alkem Laboratories Limited

+64.35 (+1.08%)

USD 728.94B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-14.95 (-0.87%)

USD 464.59B
AJANTPHARM:NSE Ajanta Pharma Limited

+117.35 (+3.78%)

USD 402.62B

ETFs Containing DIVISLAB:NSE

KMED 0.00 % 0.79 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 37.28% 54% F 66% D+
Dividend Return 0.77% 68% D+ 60% D-
Total Return 38.05% 57% F 66% D+
Trailing 12 Months  
Capital Gain 43.21% 38% F 55% F
Dividend Return 0.80% 63% D 53% F
Total Return 44.01% 41% F 55% F
Trailing 5 Years  
Capital Gain 220.93% 46% F 50% F
Dividend Return 6.57% 62% D 47% F
Total Return 227.50% 48% F 50% F
Average Annual (5 Year Horizon)  
Capital Gain 22.82% 38% F 33% F
Dividend Return 23.37% 36% F 33% F
Total Return 0.55% 50% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 42.11% 59% D- 61% D-
Risk Adjusted Return 55.51% 46% F 32% F
Market Capitalization 1,427.11B 99% N/A 97% N/A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector